Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
The New England Journal of Medicine
|
April 11, 2019
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease
David Henley, Nandini Raghavan, Reisa Sperling, et al.
The Clinical Journal of Pain
|
January 14, 2015
SCN9A Variants May be Implicated in Neuropathic Pain Associated With Diabetic Peripheral Neuropathy and Pain Severity
Qingqin S Li, Peter Cheng, Reyna Favis, et al.
International Journal of Molecular Sciences
|
November 14, 2023
Targeting Progranulin as an Immuno-Neurology Therapeutic Approach
Maria A Boylan, Andrew Pincetic, Gary Romano, et al.
BMC Genomics
|
September 1, 2023
Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat
Qingqin S Li, Stephan Francke, Jan Snoeys, et al.
Clinical Drug Investigation
|
April 21, 2015
Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men
Prasarn Manitpisitkul, Arthur Mayorga, Kevin Shalayda, et al.
Journal of Neurochemistry
|
September 3, 2015
Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio
J Randall Slemmon, Alice Shapiro, Marc Mercken, et al.
The Clinical Journal of Pain
|
May 7, 2016
Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study
Hao Wang, Gary Romano, Margaret Fedgchin, et al.
Pain Reports
|
February 3, 2018
TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study
Prasarn Manitpisitkul, Michael Brandt, Christopher M Flores, et al.
Scandinavian Journal of Pain
|
May 26, 2018
A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep)
Prasarn Manitpisitkul, Christopher M Flores, John A Moyer, et al.
Neurology
|
July 11, 2014
Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial
Hao Wang, Gary Romano, Mary Ellen Frustaci, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
The New England Journal of Medicine
|
April 11, 2019
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease
David Henley, Nandini Raghavan, Reisa Sperling, et al.
The Clinical Journal of Pain
|
January 14, 2015
SCN9A Variants May be Implicated in Neuropathic Pain Associated With Diabetic Peripheral Neuropathy and Pain Severity
Qingqin S Li, Peter Cheng, Reyna Favis, et al.
International Journal of Molecular Sciences
|
November 14, 2023
Targeting Progranulin as an Immuno-Neurology Therapeutic Approach
Maria A Boylan, Andrew Pincetic, Gary Romano, et al.
BMC Genomics
|
September 1, 2023
Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat
Qingqin S Li, Stephan Francke, Jan Snoeys, et al.
Clinical Drug Investigation
|
April 21, 2015
Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men
Prasarn Manitpisitkul, Arthur Mayorga, Kevin Shalayda, et al.
Journal of Neurochemistry
|
September 3, 2015
Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio
J Randall Slemmon, Alice Shapiro, Marc Mercken, et al.
The Clinical Journal of Pain
|
May 7, 2016
Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study
Hao Wang, Gary Romano, Margaret Fedgchin, et al.
Pain Reports
|
February 3, 2018
TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study
Prasarn Manitpisitkul, Michael Brandt, Christopher M Flores, et al.
Scandinavian Journal of Pain
|
May 26, 2018
A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep)
Prasarn Manitpisitkul, Christopher M Flores, John A Moyer, et al.
Neurology
|
July 11, 2014
Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial
Hao Wang, Gary Romano, Mary Ellen Frustaci, et al.
Page
of 2